B
Barbara A. Biedrzycki
Researcher at Johns Hopkins University
Publications - 30
Citations - 8779
Barbara A. Biedrzycki is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 14, co-authored 29 publications receiving 7219 citations. Previous affiliations of Barbara A. Biedrzycki include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation
Elizabeth M. Jaffee,Ralph H. Hruban,Barbara A. Biedrzycki,Daniel A. Laheru,K G Schepers,Patricia R. Sauter,Marti Goemann,J. Coleman,Louise B. Grochow,Ross C. Donehower,Keith D. Lillemoe,Seamus O'Reilly,Ross A. Abrams,Drew M. Pardoll,John L. Cameron,Charles J. Yeo +15 more
TL;DR: This vaccine approach seems to induce dose-dependent systemic antitumor immunity as measured by increased postvaccination DTH responses against autologous tumor cells in three patients who had received >or= 10 x 10(7) vaccine cells.
Journal ArticleDOI
A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation
Eric R. Lutz,Charles J. Yeo,Keith D. Lillemoe,Barbara A. Biedrzycki,Barry Kobrin,Joseph M. Herman,Elizabeth A. Sugar,Steven Piantadosi,John L. Cameron,Sara Solt,Beth Onners,Irena Tartakovsky,Miri Choi,Rajni Sharma,Peter B. Illei,Ralph H. Hruban,Ross A. Abrams,Dung T. Le,Elizabeth M. Jaffee,Elizabeth M. Jaffee,Daniel A. Laheru +20 more
TL;DR: An immunotherapy approach integrated with chemoradiation is safe and demonstrates an overall survival that compares favorably with published data for resected pancreatic adenocarcinoma.
Journal ArticleDOI
Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
Daniel A. Laheru,Eric R. Lutz,James M. Burke,Barbara A. Biedrzycki,Sara Solt,Beth Onners,Irena Tartakovsky,John Nemunaitis,Dung T. Le,Elizabeth A. Sugar,Kristen Hege,Elizabeth M. Jaffee +11 more
TL;DR: Findings support additional investigation of cyclophosphamide with CG8020/CG2505 immunotherapy in patients with advanced pancreatic cancer and support the use of chemotherapy and immunotherapy alone.
Journal ArticleDOI
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Leisha A. Emens,Justin M. Asquith,James M. Leatherman,Barry Kobrin,Silvia Petrik,Marina Laiko,Joy Levi,Maithili M. Daphtary,Barbara A. Biedrzycki,Antonio C. Wolff,Vered Stearns,Mary L. Disis,Xiaobu Ye,Steven Piantadosi,John H. Fetting,Nancy E. Davidson,Elizabeth M. Jaffee +16 more
TL;DR: First, immunotherapy with an allogeneic, HER2-positive, GM-CSF-secreting breast tumor vaccine alone or with CY and DOX is safe and induces Her2-specific immunity in patients with metastatic breast cancer.